Sprint Bioscience
Building value in drug development
- CEO: Anders Åberg
- First investment year: 2010
- Fund: Stockholm
- Business sector: Life Science

Sprint Bioscience develops pharmaceuticals in the areas of cancer and metabolism working with a broad portfolio of projects into the preclinical stage. The goal is to enter into commercial partnerships with larger pharmaceutical companies at an early phase.